ArticleInternational journal for parasitology. Drugs and drug resistance2020
Where are all the anthelmintics? Challenges and opportunities on the path to new anthelmintics.
Article in International journal for parasitology. Drugs and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Halogenation of neolignan scaffolds reveals stage-specific anthelmintic activity against Haemonchus contortus.International journal for parasitology. Drugs and drug resistance · 2026Article
- Deep phenotypic profiling uncovers cryptic effects of antifilarial drugs.PLoS pathogens · 2026Article
- Anthelmintic resistance in gastrointestinal nematodes of small ruminants in Southern Africa: a review and comparative analysis.Veterinary research communications · 2026Review
- Pharmacokinetic and Pharmacodynamic Assessments of the Ivermectin and Levamisole Combination to Control Resistant Nematodes in Cattle.Pharmaceutics · 2026Article
- Microbiome responses to anthelmintic treatment depend on pre-treatment helminth infection status in young Ethiopian children.Communications medicine · 2026Article
- Cloning, expression and characterisation of short-chain dehydrogenase/reductase SDR12 (A0A7I5E7J1) from a parasitic nematode Haemonchus contortus.Scientific reports · 2026Article
- Deep phenotypic profiling uncovers cryptic effects of antifilarial drugs.bioRxiv : the preprint server for biology · 2026Article
- Cancer in disguise: a parasite within.The EMBO journal · 2026Review
- Chemical perturbation reveals a cytoskeletal-trafficking vulnerability inFrontiers in pharmacology · 2026Article
- Anthelmintics Derived from the Kinase Inhibitor SGI-1776 for the Treatment of Gastrointestinal Worm Infections.ACS infectious diseases · 2025Article
- Experimental validation of RNA interference technologies for improved control of barber's pole worm.Veterinary research · 2025Article
- Magnolol and Honokiol Are Novel Antiparasitic Compounds fromACS omega · 2025Article
- Drug screens using the nematode Caenorhabditis elegans.Genetics · 2025Review
- Phytochemical-Mediated Modulation of Doramectin Pharmacology in Sheep: Exploring the Cinnamaldehyde-Pink Grapefruit Combination.Animals : an open access journal from MDPI · 2025Article
- Advances in Anthelmintic Target Identification.International journal of molecular sciences · 2025Review
- Prediction and Prioritisation of Novel Anthelmintic Candidates from Public Databases Using Deep Learning and Available Bioactivity Data Sets.International journal of molecular sciences · 2025Article
- Article
- The Anthelmintic Activity of Stonefish (Toxins · 2025Article
- A new class of natural anthelmintics targeting lipid metabolism.Nature communications · 2025Article
- Anthelmintic efficacy of mebendazole and levamisole in Olive Baboon (Papio anubis) infected with Trichuris trichiura.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Control of helminth parasites is a key challenge for human and veterinary medicine. In the absence of effective vaccines and adequate sanitation, prophylaxis and treatment commonly rely upon anthelmintics. There are concerns about the development of drug resistance, side-effects, lack of efficacy and cost-effectiveness that drive the need for new classes of anthelmintics. Despite this need, only three new drug classes have reached the animal market since 2000 and no new classes of anthelmintic have been approved for human use. So where are all the anthelmintics? What are the barriers to anthelmintic discovery, and what emerging opportunities can be used to address this? This was a discussion group focus at the 2019 8th Consortium for Anthelmintic Resistance and Susceptibility (CARS) in Wisconsin, USA. Here we report the findings of the group in the broader context of the human and veterinary anthelmintic discovery pipeline, highlighting challenges unique to antiparasitic drug discovery. We comment on why the development of novel anthelmintics has been so rare. Further, we discuss potential opportunities for drug development moving into the 21st Century.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.